CA2904847C - Engineered anti-tgf-beta antibodies and antigen-binding fragments - Google Patents

Engineered anti-tgf-beta antibodies and antigen-binding fragments Download PDF

Info

Publication number
CA2904847C
CA2904847C CA2904847A CA2904847A CA2904847C CA 2904847 C CA2904847 C CA 2904847C CA 2904847 A CA2904847 A CA 2904847A CA 2904847 A CA2904847 A CA 2904847A CA 2904847 C CA2904847 C CA 2904847C
Authority
CA
Canada
Prior art keywords
antigen
human
binding fragments
antibodies
tgf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2904847A
Other languages
English (en)
French (fr)
Other versions
CA2904847A1 (en
Inventor
Ronnie WEI
Aaron MOULIN
Magali Mathieu
Clark Pan
Sunghae PARK
Huawei Qiu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genzyme Corp
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of CA2904847A1 publication Critical patent/CA2904847A1/en
Application granted granted Critical
Publication of CA2904847C publication Critical patent/CA2904847C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00113—Growth factors
    • A61K39/001134—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA2904847A 2013-03-11 2014-03-11 Engineered anti-tgf-beta antibodies and antigen-binding fragments Active CA2904847C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361776430P 2013-03-11 2013-03-11
US61/776,430 2013-03-11
PCT/US2014/023274 WO2014164709A2 (en) 2013-03-11 2014-03-11 Engineered anti-tgf-beta antibodies and antigen-binding fragments

Publications (2)

Publication Number Publication Date
CA2904847A1 CA2904847A1 (en) 2014-10-09
CA2904847C true CA2904847C (en) 2021-06-01

Family

ID=51659302

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2904847A Active CA2904847C (en) 2013-03-11 2014-03-11 Engineered anti-tgf-beta antibodies and antigen-binding fragments

Country Status (26)

Country Link
US (2) US9783604B2 (https=)
EP (2) EP2971048B1 (https=)
JP (1) JP6495884B2 (https=)
KR (1) KR102258457B1 (https=)
CN (1) CN105229160B (https=)
AR (1) AR095240A1 (https=)
AU (2) AU2014249051B2 (https=)
BR (1) BR112015021595A2 (https=)
CA (1) CA2904847C (https=)
CY (1) CY1121412T1 (https=)
DK (1) DK2971048T3 (https=)
ES (2) ES2845215T3 (https=)
HR (1) HRP20190201T1 (https=)
HU (1) HUE042020T2 (https=)
IL (1) IL241404B (https=)
LT (1) LT2971048T (https=)
MX (1) MX365385B (https=)
PL (1) PL2971048T4 (https=)
PT (1) PT2971048T (https=)
RU (1) RU2681502C2 (https=)
SG (2) SG11201507279XA (https=)
SI (1) SI2971048T1 (https=)
TR (1) TR201901415T4 (https=)
TW (2) TWI613216B (https=)
UY (1) UY35384A (https=)
WO (1) WO2014164709A2 (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2921805C (en) 2013-08-22 2023-03-07 Acceleron Pharma, Inc. Tgf-beta receptor type ii variants and uses thereof
EP4400516A1 (en) 2014-12-15 2024-07-17 The Regents of the University of California Bispecific or-gate chimeric antigen receptor responsive to cd19 and cd20
EP3234120B1 (en) 2014-12-15 2025-09-03 The Regents of the University of California Cytotoxic molecules responsive to intracellular ligands for selective t cell mediated killing
TWI726870B (zh) 2015-03-04 2021-05-11 美商健臻公司 具有高親和性、結合性及專一性之結合轉形生長因子-β１的ｓｃＦｖ-Ｆｃ二聚體
TWI733661B (zh) 2015-03-04 2021-07-21 美商健臻公司 以高親合性、結合性及特異性結合轉化生長因子－β１的經修飾ＩｇＧ抗體
HK1256638A1 (zh) 2015-08-04 2019-09-27 Acceleron Pharma Inc. 用於治疗骨髓增生性病症的方法
DK3368571T5 (da) * 2015-10-30 2024-09-30 Univ California Transformerende, vækstfaktor-beta-responsive polypeptider og fremgangsmåder til anvendelse deraf
ES2904553T3 (es) * 2015-10-30 2022-04-05 Hoffmann La Roche Fragmentos de anticuerpo modificados con bisagra y procedimientos de preparación
WO2017201036A1 (en) 2016-05-17 2017-11-23 Genentech, Inc. Stromal gene signatures for diagnosis and use in immunotherapy
GB201610044D0 (en) 2016-06-08 2016-07-20 Ucb Biopharma Sprl Antibodies
JP2019533003A (ja) * 2016-08-11 2019-11-14 プレシセラ，インコーポレイテッド ＴＧＦ−βアンタゴニストコンジュゲート
JP2019530440A (ja) 2016-09-02 2019-10-24 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア インターロイキン６受容体α結合単鎖可変断片を含む方法および組成物
LT3628049T (lt) 2017-05-04 2023-08-25 Acceleron Pharma Inc. Tgf-beta ii tipo receptoriaus sulieti baltymai ir jų panaudojimo būdai
ES2984919T3 (es) 2017-11-06 2024-10-31 Hoffmann La Roche Procedimientos diagnósticos y terapéuticos para el cáncer
MX2021000347A (es) * 2018-07-11 2021-04-19 Scholar Rock Inc Inhibidores de tgf?1 selectivos de isoforma, de alta afinidad y usos de los mismos.
BR112022003412A2 (pt) 2019-08-28 2022-05-24 Chugai Pharmaceutical Co Ltd Anticorpos anti-tgf-beta 1 latente de espécies cruzadas e métodos de uso
CN114728072A (zh) 2019-10-23 2022-07-08 库尔生物制药有限公司 TGF-β多肽
TWI867190B (zh) * 2020-03-19 2024-12-21 美商建南德克公司 同功型選擇性抗-TGF-β抗體及其使用方法
US20220119513A1 (en) * 2020-06-08 2022-04-21 Zoetis Services Llc Anti-tgfb antibodies and therapeutic uses thereof
WO2022115611A1 (en) 2020-11-25 2022-06-02 Catamaran Bio, Inc. Cellular therapeutics engineered with signal modulators and methods of use thereof
US20240101675A1 (en) * 2021-01-21 2024-03-28 Biolojic Design Ltd. Dual binding antibodies, methods of producing dual binding antibodies, and uses thereof
CN112851819B (zh) * 2021-01-25 2023-08-11 华中科技大学同济医学院附属同济医院 结合小鼠PD-L1和TGF-β的双特异性抗体及其制备方法与应用
EP4291227A2 (en) * 2021-02-15 2023-12-20 Takeda Pharmaceutical Company Limited Cell therapy compositions and methods for modulating tgf-b signaling
CN113480645B (zh) * 2021-07-16 2022-11-11 甘肃中科博瑞生物工程有限公司 一种抗幽门螺旋杆菌重组抗体、制备方法及用途
WO2023080900A1 (en) 2021-11-05 2023-05-11 Genentech, Inc. Methods and compositions for classifying and treating kidney cancer
WO2024077166A1 (en) 2022-10-05 2024-04-11 Genentech, Inc. Methods and compositions for classifying and treating lung cancer
WO2024077095A1 (en) 2022-10-05 2024-04-11 Genentech, Inc. Methods and compositions for classifying and treating bladder cancer

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5571714A (en) * 1988-12-22 1996-11-05 Celtrix Pharmaceuticals, Inc. Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
JP4124815B2 (ja) 1991-10-31 2008-07-23 ホワイトヘッド インスティチュート フォー バイオメディカル リサーチ ＴＧＦ−β型受容体ｃＤＮＡおよびその用途
US6008011A (en) 1991-10-31 1999-12-28 Whitehead Institute For Biomedical Research TGF-β type II receptor cDNAs
RU2157406C2 (ru) * 1993-08-10 2000-10-10 Биофарм Гезелльшафт Цур Биотехнологишен Энтвиклунг Фон Фармака Мбх НОВЫЙ ФАКТОР РОСТА/ДИФФЕРЕНЦИАЦИИ TGF-β-СЕМЕЙСТВА
IL110589A0 (en) 1993-08-10 1994-11-11 Bioph Biotech Entw Pharm Gmbh Growth/differentiation factor of the TGF- beta family
GB9601081D0 (en) * 1995-10-06 1996-03-20 Cambridge Antibody Tech Specific binding members for human transforming growth factor beta;materials and methods
CA2301166A1 (en) 1997-07-24 1999-02-04 Yuan-Peng Zhang Liposomal compositions for the delivery of nucleic acid catalysts
WO2000040227A2 (en) 1999-01-05 2000-07-13 University Of Utah Methods for treating conditions associated with the accumulation of excess extracellular matrix
US7763580B2 (en) 1999-01-05 2010-07-27 University Of Utah Research Foundation Methods for treating conditions associated with the accumulation of excess extracellular matrix
US6492497B1 (en) 1999-04-30 2002-12-10 Cambridge Antibody Technology Limited Specific binding members for TGFbeta1
WO2001066140A1 (en) 2000-03-09 2001-09-13 Genzyme Corporation Use of tgf-beta antagonists to treat or to prevent loss of renal function
AU2003209308A1 (en) 2002-01-22 2003-09-02 Genzyme Corporation Use of tgf-beta antagonists to treat or to prevent chronic transplant rejection
EP1620128A1 (en) 2003-04-30 2006-02-01 Genzyme Corporation Tgf-beta antagonists combined with renin-angiotensin-aldosteron-system antagonists for treating renal insufficiency
WO2006086469A2 (en) 2005-02-08 2006-08-17 Genzyme Corporation Antibodies to tgfbeta
EP1948675B1 (en) 2005-10-25 2014-07-30 The Johns Hopkins University Methods and compositions for the treatment of marfan syndrome and associated disorders
KR101516823B1 (ko) * 2006-03-17 2015-05-07 바이오겐 아이덱 엠에이 인코포레이티드 안정화된 폴리펩티드 조성물
WO2007121233A1 (en) 2006-04-12 2007-10-25 Genzyme Corporation Methods of treating autoimmune diseases
DK2083863T3 (da) 2006-10-03 2015-06-22 Genzyme Corp Antistoffer mod tgf-beta til anvendelse til behandling af spædbørn med risiko for udvikling af bronkopulmonal dysplasi
US20120294868A1 (en) 2009-04-24 2012-11-22 Edwards James R Anti-tgf-beta induction of bone cell function and bone growth
ME02464B (me) 2010-03-12 2017-02-20 Genzyme Corp Kombinovana terapija za lečenje raka dojke
MY165160A (en) 2010-09-01 2018-02-28 Genzyme Corp TREATMENT OF MYOCARDIAL INFARCTION USING TGF-ß ANTAGONISTS

Also Published As

Publication number Publication date
UY35384A (es) 2014-10-31
KR102258457B1 (ko) 2021-05-31
EP3415633B1 (en) 2020-10-28
ES2845215T3 (es) 2021-07-26
US9783604B2 (en) 2017-10-10
MX365385B (es) 2019-05-31
CN105229160A (zh) 2016-01-06
IL241404A0 (en) 2015-11-30
AU2018203261A1 (en) 2018-05-31
KR20150126397A (ko) 2015-11-11
CA2904847A1 (en) 2014-10-09
ES2713505T3 (es) 2019-05-22
PL2971048T3 (pl) 2019-05-31
TWI613216B (zh) 2018-02-01
JP2016512521A (ja) 2016-04-28
IL241404B (en) 2018-11-29
TR201901415T4 (tr) 2019-02-21
MX2015012541A (es) 2016-02-10
JP6495884B2 (ja) 2019-04-03
TWI664979B (zh) 2019-07-11
CN105229160B (zh) 2020-06-23
TW201803592A (zh) 2018-02-01
BR112015021595A2 (pt) 2017-10-10
SI2971048T1 (sl) 2019-03-29
CY1121412T1 (el) 2020-05-29
EP2971048A4 (en) 2016-11-02
SG11201507279XA (en) 2015-10-29
EP2971048A2 (en) 2016-01-20
WO2014164709A3 (en) 2014-12-24
EP2971048B1 (en) 2018-10-31
TW201522369A (zh) 2015-06-16
WO2014164709A2 (en) 2014-10-09
LT2971048T (lt) 2019-02-25
EP3415633A1 (en) 2018-12-19
US20160017026A1 (en) 2016-01-21
HUE042020T2 (hu) 2019-06-28
DK2971048T3 (en) 2019-02-25
AR095240A1 (es) 2015-09-30
PT2971048T (pt) 2019-02-06
US20170342144A1 (en) 2017-11-30
SG10201707021RA (en) 2017-10-30
RU2681502C2 (ru) 2019-03-06
HRP20190201T1 (hr) 2019-03-22
PL2971048T4 (pl) 2019-05-31
AU2018203261B2 (en) 2020-03-26
RU2015143156A (ru) 2017-04-13
AU2014249051B2 (en) 2018-02-15
AU2014249051A1 (en) 2015-10-01
US10730936B2 (en) 2020-08-04
HK1220731A1 (en) 2017-05-12

Similar Documents

Publication Publication Date Title
CA2904847C (en) Engineered anti-tgf-beta antibodies and antigen-binding fragments
NZ631098A (en) Anti-hepcidin antibodies and uses thereof
EP3882268A4 (en) ANTI-CD73 ANTIBODY, ANTIGEN-BINDING FRAGMENT THEREOF AND APPLICATION THEREOF
AU2018256487A1 (en) Antibodies that bind to TL1A and their uses
EP3689909A4 (en) Tigit antibody, antigen-binding fragment thereof, and medical use thereof
EP3029069A4 (en) Anti-human cd26 monoclonal antibody or antigen-binding fragment thereof
WO2015091853A3 (en) Human anti-cd40 human antibodies
PH12016501212B1 (en) Human anti-il-33 neutralizing monoclonal antibody
WO2017132562A8 (en) Antigen binding proteins that bind pd-l1
EP3081576A4 (en) Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
EA201591974A1 (ru) Антитела человека, связывающиеся с g-белком rsv
NZ739090A (en) Bispecific antibodies specific for pd1 and tim3
MX2014001799A (es) Anticuerpos sin fc qie comprenden dos fragmentos fab y metodos de uso.
EP3060581A4 (en) Anti-pd-l1 monoclonal antibodies and fragments thereof
WO2011131746A3 (en) Heterodimeric antibody fc-containing proteins and methods for production thereof
MX354359B (es) Variantes de fragmento cristalizable (fc) de los anticuerpos.
WO2014160160A3 (en) Antibody drug conjugates and corresponding antibodies
WO2011117648A3 (en) Disulfide stabilised antibodies and fragments thereof
NZ710422A (en) Protein combination-based fv library, and preparation method therefor
EA201990673A1 (ru) Антитела, специфически связывающиеся с il-17a, и их функциональные фрагменты
WO2015075269A9 (en) Antibodies against ccr9 and applications thereof
EP4079760A3 (en) Antibodies against clostridium difficile toxins and methods of using the same
WO2013115410A3 (en) Anti-phospholipase d4 antibody
HK1250649A1 (zh) 用於治疗白血病的抗-s100a8
EP3242895A4 (en) A novel anti-egfr monoclonal antibody, method of making, and use thereof

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190308

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 11TH ANNIV.) - STANDARD

Year of fee payment: 11

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250217

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250217